IXHL vs. CRVO, PRLD, IMAB, INCR, SKYE, RGLS, ACET, PRQR, RPTX, and DMAC
Should you be buying Incannex Healthcare stock or one of its competitors? The main competitors of Incannex Healthcare include CervoMed (CRVO), Prelude Therapeutics (PRLD), I-Mab (IMAB), InterCure (INCR), Skye Bioscience (SKYE), Regulus Therapeutics (RGLS), Adicet Bio (ACET), ProQR Therapeutics (PRQR), Repare Therapeutics (RPTX), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical preparations" industry.
CervoMed (NASDAQ:CRVO) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
CervoMed has higher revenue and earnings than Incannex Healthcare.
25.2% of CervoMed shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 2.0% of CervoMed shares are held by company insiders. Comparatively, 14.6% of Incannex Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Incannex Healthcare had 1 more articles in the media than CervoMed. MarketBeat recorded 4 mentions for Incannex Healthcare and 3 mentions for CervoMed. Incannex Healthcare's average media sentiment score of 1.14 beat CervoMed's score of 0.51 indicating that CervoMed is being referred to more favorably in the media.
CervoMed received 3 more outperform votes than Incannex Healthcare when rated by MarketBeat users.
CervoMed's return on equity of 0.00% beat Incannex Healthcare's return on equity.
CervoMed presently has a consensus price target of $57.50, suggesting a potential upside of 133.17%. Given Incannex Healthcare's higher probable upside, equities analysts clearly believe CervoMed is more favorable than Incannex Healthcare.
CervoMed has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 8.65, indicating that its share price is 765% more volatile than the S&P 500.
Summary
CervoMed beats Incannex Healthcare on 7 of the 13 factors compared between the two stocks.
Get Incannex Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Incannex Healthcare Competitors List
Related Companies and Tools
